NCT01373294 - Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 9, 2015

Study Completion Date

December 10, 2018

Conditions

Bladder Cancer

Interventions

DRUG

Bacille Calmette-Guerrin (BCG)

Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.

DRUG

Lenalidomide

Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa